LMDX News and Press, LumiraDx Limited From 03/10/22

LumiraDx press release (NASDAQ:LMDX): Q4 Non-GAAP EPS of -$0.08. Revenue of $118.25M (+5.3% Y/Y) misses by $0.63M. For further details see: LumiraDx Non-GAAP EPS of -$0.08, revenue of $118.25M misses by $0.63M

LumiraDx Reports Fourth Quarter and Full Year 2021 Results Positive Customer Experience Drives Market Adoption and Expands Use Cases for LumiraDx's Transformative Diagnostic Solutions PR Newswire LONDON , March 10, 2022 /PRNewswire/ -- LumiraDx Limited (...

LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10 PR Newswire LONDON , March 3, 2022 /PRNewswire/ -- LumiraDx Limited  (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics comp...

LumiraDx (NASDAQ:LMDX) entered into privately negotiated subscription agreements with certain investors wherein the company agreed to sell and the investors agreed to purchase from LumiraDx $56.5M principal amount of 6.00% Convertible Senior Subordinated Notes due 2027. The pur...

LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering PR Newswire LONDON , March 1, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) announced today that it entered into privately negotiated subscription agreements with certain investors ...

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants PR Newswire LONDON ...

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test Company Announces Preliminary Revenue for Fourth Quarter and Full Year 2021...

LumiraDx CRP Test Achieves CE Marking - Rapid microfluidic immunofluorescence assay intended for the quantitative determination of C-reactive protein (CRP) in fingerstick, venous whole blood and plasma specimens within a range of 5.0 - 250.0 mg/L - Quantitative results in 4 ...

LumiraDx (NASDAQ:LMDX) announces that its SARS-CoV-2 & Flu A/B Antigen Test has achieved CE Marking. The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19. Existing respiratory tests on the LumiraDx P...

LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking - Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differen...